Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Laboratories

Division of Pfizer Inc.

Latest From Wyeth Laboratories

INTERVIEW: Hilleman Seeks Hib Partners As It Hones Focus

Indian vaccine R&D firm Hilleman Laboratories says it's talking to potential partners about the clinical testing of a new "breakthrough" vaccine formulation that could create a far cheaper, more effective way to combat Haemophilus influenzae type b (Hib) and be in production in the next three to four years.

BioPharmaceutical India

Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals

Efforts to foster innovation may have been the major theme for FDA in 2013, with new and expanded programs to expedite review of drugs for unmet medical needs dominating headlines, but senior agency officials also describe continued advances on the safety side of the regulatory equation.

BioPharmaceutical Safety

Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals

Efforts to foster innovation may have been the major theme for FDA in 2013, with new and expanded programs to expedite review of drugs for unmet medical needs dominating headlines, but senior agency officials also describe continued advances on the safety side of the regulatory equation.

BioPharmaceutical Clinical Trials

Branding Goes Global

Until recently, most pharma firms handed drugs to a network of partners for marketing, or let their local divisions figure out sales strategies. These days, companies are increasingly working from headquarters to devise a single strategy they can apply across world markets. The point of global branding is leverage. Companies hope to increase sales while decreasing costs associated with marketing, and so get maximum value from drugs, throughout carefully planned life cycles. Medical marketers are studying how consumer-goods marketers craft consistent images and messages that help products become internationally desirable brands. Firms are thinking and acting earlier, with more coordination, than ever before. Some major companies have undergone fundamental restructuring to become more effective at global branding. They're meeting frequently, defining best practices, paying more attention to pre-launch efforts and to Phase IV studies that may support claims. No one knows which practices work best. Some experts say the industry should behave more like consumer marketers, others say less. It's possible that global branding can widen corporate development choices.

BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Heidi M Hunter, VP, Global Bus. Mgr.
  • Contact Info
  • Wyeth Laboratories
    Phone: (215) 341-3905
    P.O. Box 8299 Philadelphia, PA 19101-
    USA
UsernamePublicRestriction

Register